An Open-label Extension Trial of the Long Term Safety of Oral BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
An Open-label Extension Trial of the Long Term Safety of Oral BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
The aim of this extension trial is to assess the long-term safety of BIBF 1120 treatment in patients with Idiopathic Pulmonary Fibrosis who have completed one year treatment and the follow up period in the double-blind phase III placebo controlled parent trials (1199.32 and 1199.34), who wish to continue treatment with BIBF 1120.
Inclusion criteria:
Exclusion criteria:
Essen, 45239, Germany
Freiburg/Breisgau, 79106, Germany
Großhansdorf, 22927, Germany
Aichi, Nagoya, 466-8560, Japan
Aichi, Seto, 489-8642, Japan
Gifu, Ogaki, 503-0864, Japan
Himeji, Hyogo, 670-8520, Japan
Hyogo, Kobe, 650-0047, Japan
Kanagawa, Kawasaki, 213-0015, Japan
Kanagawa, Yokohama, 236-0051, Japan
Miyagi, Sendai, 980-8574, Japan
Nara, Tenri, 632-8552, Japan
Osaka, Osaka-sayama, 589-8511, Japan
Saitama, Kumagaya, 360-0105, Japan
Sakai, Osaka, 591-8555, Japan
Tochigi, Shimotsuke, 329-0498, Japan
Tokushima, Tokushima, 770-0042, Japan
Tokyo, Bunkyo-ku, 113-8519, Japan
Tokyo, Bunkyo-ku, 113-8603, Japan
Tokyo, Kiyose, 204-0022, Japan
Tokyo, Minato-ku, 105-0001, Japan
Tokyo, Minato-ku, 105-0003, Japan
Tokyo, Ota-ku, 143-0015, Japan
Tokyo, Shinjuku-ku, 162-8555, Japan
Tottori, Yonago, 683-0826, Japan